X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-06-05 | KRON | Knobelman Deborah | Pres, Interim CEO | S - Sale | $0.87 | -24,838 | 139,422 | -15% | -$21,554 | ||||||
| M | 2024-06-27 | KRON | Bischofberger Norbert W | Pres, CEO | P - Purchase | $1.19 | +615,518 | 11,857,138 | +5% | +$733,801 | |||||
| M | 2024-06-10 | KRON | Bischofberger Norbert W | Pres, CEO | P - Purchase | $1.04 | +3,005,122 | 11,241,620 | +36% | +$3,119,081 | |||||
2024-02-21 | KRON | Olek Elizabeth A | SVP, CLINICAL SCIENCE | S - Sale | $1.05 | -7,368 | 193,275 | -4% | -$7,765 | ||||||
2024-02-21 | KRON | Lin Charles Y | SVP, RESEARCH, DEVELOPMENT | S - Sale | $1.05 | -12,036 | 234,603 | -5% | -$12,685 | ||||||
2024-02-21 | KRON | Frisbee Allison | SVP, CORP OPERATIONS, LEGAL | S - Sale | $1.05 | -12,105 | 204,510 | -6% | -$12,757 | ||||||
2024-01-04 | KRON | Dinsmore Christopher | Chief Scientific Officer | S - Sale | $1.18 | -7,366 | 260,969 | -3% | -$8,718 | ||||||
2024-01-04 | KRON | Dimartino Jorge | Chief Medical Officer, VP | S - Sale | $1.18 | -12,009 | 315,246 | -4% | -$14,214 | ||||||
2024-01-04 | KRON | Kosacz Barbara | COO, GC | S - Sale | $1.18 | -10,676 | 928,966 | -1% | -$12,636 | ||||||
2023-12-12 | KRON | Dinsmore Christopher | Chief Scientific Officer | S - Sale | $1.31 | -10,032 | 268,335 | -4% | -$13,092 | ||||||
2023-12-12 | KRON | Dimartino Jorge | Chief Medical Officer, VP | S - Sale | $1.31 | -17,367 | 327,255 | -5% | -$22,664 | ||||||
| M | 2023-11-15 | KRON | Bischofberger Norbert W | Pres, CEO | P - Purchase | $0.85 | +1,731,056 | 7,966,159 | +28% | +$1,470,395 | |||||
2023-07-06 | KRON | Dinsmore Christopher | Chief Scientific Officer | S - Sale | $1.75 | -6,634 | 278,367 | -2% | -$11,625 | ||||||
2023-07-06 | KRON | Dimartino Jorge | Chief Medical Officer, VP | S - Sale | $1.75 | -10,818 | 344,622 | -3% | -$18,956 | ||||||
2023-07-06 | KRON | Al-Wakeel Yasir B. | CFO | S - Sale | $1.75 | -9,617 | 346,102 | -3% | -$16,852 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |